Healthcare

Chimeric Therapeutics Limited fell −3.23% to A$0.150 on volume of 63.67 K with relative volume of 0.59. Market cap is A$7.19 million. There is no P/E disclosed. Diluted EPS (TTM) is −A$0.72, and diluted EPS growth (TTM YoY) is +62.07%. A 3.23% decline on …

Cynata Therapeutics Limited fell −4.62% to A$0.310 on volume of 121.95 K with relative volume of 0.47. Market cap is A$75.99 million. There is no P/E disclosed. Diluted EPS (TTM) is −A$0.04, and diluted EPS growth (TTM YoY) is +24.59%. A 4.62% decline on …

A 4.12% decline on below-average relative volume is a measured move. The deeply negative trailing EPS at −A$1.02 is striking — for a A$2.56 share price, the loss represents a substantial fraction of the share price.

Fusion Antibodies PLC shares moved lower today primarily because of a broader risk-off sentiment affecting UK small-cap biotechnology and AIM-listed healthcare stocks. Investors globally are rotating toward defensive sectors due to geopolitical uncertainty, elevated bond yields, persistentInflationconcerns, and slower global economic growth expectations.

LTR Pharma is a clinical-stage biopharmaceutical company focused on developing therapies for unmet medical needs, with a particular emphasis on men’s health. Its pipeline includes fast-acting intranasal treatments such as SPONTAN and ROXUS for erectile dysfunction, designed to deliver rapid onset of action, as …

Today, the company reported a key update with the filing of a new US provisional patent aimed at strengthening its intellectual property position around its TRP-8803 program. The filing is supported by recent Phase 2a clinical data in treatment-resistant irritable bowel syndrome (IBS), which …

The single fact provided in the headline is meaningful but limited: a 75 per cent response rate in an IBS clinical trial. Specifics on patient numbers, comparator arms, statistical robustness, response definitions, regulatory pathway and follow-up trial plans will be matters for the company’s …